These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

420 related articles for article (PubMed ID: 16195386)

  • 1. Genistein, a natural product from soy, is a potent inhibitor of transthyretin amyloidosis.
    Green NS; Foss TR; Kelly JW
    Proc Natl Acad Sci U S A; 2005 Oct; 102(41):14545-50. PubMed ID: 16195386
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Synthesis and characterization of potent bivalent amyloidosis inhibitors that bind prior to transthyretin tetramerization.
    Green NS; Palaninathan SK; Sacchettini JC; Kelly JW
    J Am Chem Soc; 2003 Nov; 125(44):13404-14. PubMed ID: 14583036
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Conformational differences between the wild type and V30M mutant transthyretin modulate its binding to genistein: implications to tetramer stability and ligand-binding.
    Trivella DB; Bleicher L; Palmieri Lde C; Wiggers HJ; Montanari CA; Kelly JW; Lima LM; Foguel D; Polikarpov I
    J Struct Biol; 2010 Jun; 170(3):522-31. PubMed ID: 20211733
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Specific disruption of transthyretin(105-115) fibrilization using "stabilizing" inhibitors of transthyretin amyloidogenesis.
    Liang Y; Ore MO; Morin S; Wilson DJ
    Biochemistry; 2012 Apr; 51(16):3523-30. PubMed ID: 22482799
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Kinetic stabilization of an oligomeric protein by a single ligand binding event.
    Wiseman RL; Johnson SM; Kelker MS; Foss T; Wilson IA; Kelly JW
    J Am Chem Soc; 2005 Apr; 127(15):5540-51. PubMed ID: 15826192
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Native state kinetic stabilization as a strategy to ameliorate protein misfolding diseases: a focus on the transthyretin amyloidoses.
    Johnson SM; Wiseman RL; Sekijima Y; Green NS; Adamski-Werner SL; Kelly JW
    Acc Chem Res; 2005 Dec; 38(12):911-21. PubMed ID: 16359163
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A substructure combination strategy to create potent and selective transthyretin kinetic stabilizers that prevent amyloidogenesis and cytotoxicity.
    Choi S; Reixach N; Connelly S; Johnson SM; Wilson IA; Kelly JW
    J Am Chem Soc; 2010 Feb; 132(4):1359-70. PubMed ID: 20043671
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Kinetic stabilization of an oligomeric protein under physiological conditions demonstrated by a lack of subunit exchange: implications for transthyretin amyloidosis.
    Wiseman RL; Green NS; Kelly JW
    Biochemistry; 2005 Jun; 44(25):9265-74. PubMed ID: 15966751
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Semi-quantitative models for identifying potent and selective transthyretin amyloidogenesis inhibitors.
    Connelly S; Mortenson DE; Choi S; Wilson IA; Powers ET; Kelly JW; Johnson SM
    Bioorg Med Chem Lett; 2017 Aug; 27(15):3441-3449. PubMed ID: 28625364
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Native state stabilization by NSAIDs inhibits transthyretin amyloidogenesis from the most common familial disease variants.
    Miller SR; Sekijima Y; Kelly JW
    Lab Invest; 2004 May; 84(5):545-52. PubMed ID: 14968122
    [TBL] [Abstract][Full Text] [Related]  

  • 11. AG10 inhibits amyloidogenesis and cellular toxicity of the familial amyloid cardiomyopathy-associated V122I transthyretin.
    Penchala SC; Connelly S; Wang Y; Park MS; Zhao L; Baranczak A; Rappley I; Vogel H; Liedtke M; Witteles RM; Powers ET; Reixach N; Chan WK; Wilson IA; Kelly JW; Graef IA; Alhamadsheh MM
    Proc Natl Acad Sci U S A; 2013 Jun; 110(24):9992-7. PubMed ID: 23716704
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Orally administered diflunisal stabilizes transthyretin against dissociation required for amyloidogenesis.
    Sekijima Y; Dendle MA; Kelly JW
    Amyloid; 2006 Dec; 13(4):236-49. PubMed ID: 17107884
    [TBL] [Abstract][Full Text] [Related]  

  • 13. R104H may suppress transthyretin amyloidogenesis by thermodynamic stabilization, but not by the kinetic mechanism characterizing T119 interallelic trans-suppression.
    Sekijima Y; Dendle MT; Wiseman RL; White JT; D'Haeze W; Kelly JW
    Amyloid; 2006 Jun; 13(2):57-66. PubMed ID: 16911959
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tafamidis, a potent and selective transthyretin kinetic stabilizer that inhibits the amyloid cascade.
    Bulawa CE; Connelly S; Devit M; Wang L; Weigel C; Fleming JA; Packman J; Powers ET; Wiseman RL; Foss TR; Wilson IA; Kelly JW; Labaudinière R
    Proc Natl Acad Sci U S A; 2012 Jun; 109(24):9629-34. PubMed ID: 22645360
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Potent and selective structure-based dibenzofuran inhibitors of transthyretin amyloidogenesis: kinetic stabilization of the native state.
    Petrassi HM; Johnson SM; Purkey HE; Chiang KP; Walkup T; Jiang X; Powers ET; Kelly JW
    J Am Chem Soc; 2005 May; 127(18):6662-71. PubMed ID: 15869287
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nearly 200 X-ray crystal structures of transthyretin: what do they tell us about this protein and the design of drugs for TTR amyloidoses?
    Palaninathan SK
    Curr Med Chem; 2012; 19(15):2324-42. PubMed ID: 22471981
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prevention of transthyretin amyloid disease by changing protein misfolding energetics.
    Hammarström P; Wiseman RL; Powers ET; Kelly JW
    Science; 2003 Jan; 299(5607):713-6. PubMed ID: 12560553
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Kinetic stabilization of the native state by protein engineering: implications for inhibition of transthyretin amyloidogenesis.
    Foss TR; Kelker MS; Wiseman RL; Wilson IA; Kelly JW
    J Mol Biol; 2005 Apr; 347(4):841-54. PubMed ID: 15769474
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Chromium(III) ion and thyroxine cooperate to stabilize the transthyretin tetramer and suppress in vitro amyloid fibril formation.
    Sato T; Ando Y; Susuki S; Mikami F; Ikemizu S; Nakamura M; Suhr O; Anraku M; Kai T; Suico MA; Shuto T; Mizuguchi M; Yamagata Y; Kai H
    FEBS Lett; 2006 Jan; 580(2):491-6. PubMed ID: 16386248
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pathogenesis of and therapeutic strategies to ameliorate the transthyretin amyloidoses.
    Sekijima Y; Kelly JW; Ikeda S
    Curr Pharm Des; 2008; 14(30):3219-30. PubMed ID: 19075702
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.